Trauma is a leading cause of death worldwide in persons under 44 years of age, and uncontrolled haemorrhage is the most common preventable cause of death in this patient group. The transfusion management of trauma haemorrhage is unrecognisable from 20 years ago. Changes in clinical practice have been driven primarily by an increased understanding of the pathophysiology of trauma-induced coagulopathy (TIC), which is associated with poor clinical outcomes, including a 3-to 4-fold increased risk of death. Targeting this coagulopathy alongside changes to surgical and anaesthetic practices (an overarching strategy known as damage control surgery/damage control resuscitation) has led to a significant reduction in mortality rates over the last two decades. This narrative review will discuss the transfusion practices that are currently used for trauma haemorrhage and the evidence that supports these practices.
Globally, trauma is one of the leading causes of death in persons under 44 years of age (Centers for Disease Control and Prevention, National Center for Injury Prevention and Control (2017) . It is estimated that, across the world, one person dies every 3 min from injury (Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, 2017) and up to 40% of these deaths are due to uncontrolled bleeding or its consequences (Curry et al, 2011) . Death from haemorrhage is frequently early -with as many as six in every 10 deaths occurring within the first three hours of injury . Additionally, the financial burden of trauma to health systems is large -a cross sectional study conducted in the UK in 2012 estimated the annual cost of treating trauma haemorrhage to be in excess of £148M, and this figure did not include the costs of rehabilitation and lost income from patients not returning to work (Campbell et al, 2015) .
The transfusion management of trauma haemorrhage is unrecognisable from 20 years ago. The changes in clinical practice have been driven primarily by the increased understanding of the pathophysiology of trauma-induced coagulopathy (TIC). Present in up to a quarter of trauma patients, TIC is associated with significantly poorer clinical outcomes, including increased need for major haemorrhage therapy, increased risk of organ failure and, most importantly, a 3-to 4-fold increase risk of death (Brohi et al, 2003; MacLeod et al, 2003; Maegele et al, 2007) . Targeting coagulopathy alongside changes to surgical and anaesthetic practices (an overarching strategy known as damage control surgery/damage control resuscitation) has led to a significant reduction in mortality rates over the last two decades .
This narrative review will discuss the transfusion practices that are currently used for trauma haemorrhage and the evidence that supports these practices. We will also discuss the uncertainties that exist and the potential changes that could take place over the next decade.
Traumatic coagulopathy
The understanding of the mechanisms by which TIC develops continues to evolve but it is clear that the condition occurs in the acute phase after major haemorrhage and severe tissue injury independent of fluid resuscitation, which, in itself, can result in an iatrogenic dilutional coagulopathy (Bolliger et al, 2010) . A detailed description of the changes that take place after injury to the clotting systems and how these are tightly inter-related to inflammatory and immune responses is beyond the scope of this review, and has been reviewed in detail elsewhere Lord et al, 2014; Davenport & Brohi, 2016) .
Briefly, TIC describes the overall failure of the coagulation system to sustain haemostasis after major injury (see Fig 1) , and is characterised by both an early endogenous coagulopathy -acute traumatic coagulopathy (ATC) -primarily mediated by protein C activation , as well as a systemic coagulopathy exacerbated by sub-optimal resuscitation (i.e. a dilutional coagulopathy), concomitant acidosis, hypothermia and genetic influences . Clotting changes evident in ATC include normal to high levels of thrombin generation (Dunbar & Chandler, 2009; Cardenas et al, 2014) ; significant fibrinolysis secondary to the release of tissue plasminogen activator (tPA) from the endothelium (Chapman et al, 2016) or other cell surface receptors, e.g. S100A10 (Gall et al, 2018) ; and rapid depletion of fibrinogen (Davenport & Brohi, 2016) . High thrombin generation, in concert with tissue hypoxia, leads to activation of the endothelium causing upregulation of thrombomodulin (TM) and subsequent protein C activation. In turn, activated protein C leads to inactivation of factor (F) Va and FVIIIa and depletion of fibrinogen (both effects potentiating a hypocoagulable bleeding state) , as well as inhibition of plasminogen activator inhibitor-1 (PAI-1) which increases fibrinolysis -a phenomenon known to be significantly activated in many patients after trauma (Brohi et al, 2008; Raza et al, 2013) .
Endothelial activation is central to traumatic coagulopathy, acting as an important link between the coagulation and inflammatory responses. Markers of endothelial activation, such as soluble-TM and syndecan-1, are high (Johansson et al, 2011) and are associated with shock and poor clinical outcomes (Kozar et al, 2011) . Over time, persistent endothelial activation leads to a prothrombotic state, and partly explains the high thrombosis rates in severe trauma (Cap & Hunt, 2014) . In addition to endothelial and coagulation dysfunction, platelets are also adversely affected by injury. Several observational studies have demonstrated the presence of platelet dysfunction -most commonly shown by a reduction in aggregation with ADP (Solomon et al, 2011; Kutcher et al, 2012) although a more global defect has been reported by others (Vuillamy et al, 2017) . Recent work has shown that platelet dysfunction can increase clot susceptibility to fibrinolysis (possibly due to loss of platelet-stored PAI-1 at the site of injury) (Moore et al, 2015) . However, much more needs to be learnt about the reasons why, and indeed how, platelet function is altered by severe injury.
General clinical management strategies for trauma haemorrhage

Damage control resuscitation
Damage control resuscitation is a key management strategy employed by trauma teams to manage significant haemorrhage after injury. It is defined by rapid surgical or radiological haemorrhage control with an empiric and balanced resuscitation of blood and blood components in high ratios and avoidance of crystalloids (Naumann et al, 2018; Pohlman et al, 2018) . The premise of this haemostatic strategy is to prevent the coagulopathy caused by resuscitation, although it may have a limited effect on reversal of traumatic coagulopathy during active bleeding (Khan et al, 2015) .
Major haemorrhage protocols
Major haemorrhage protocols (MHP) were introduced to improve the speed and consistency of delivery of red blood cells (RBCs) and other blood components to severely bleeding patients, and have been shown in a number of observational studies to improve outcomes, including mortality (Young et al, 2011) [In the US and other countries, the term massive transfusion protocol (MTP) may be used in place of MHP, although this often describes only RBC and blood component therapy, rather than additional adjunctive haemostatic therapy such as tranexamic acid (TXA)]. MHPs provide a clear framework to facilitate a co-ordinated response by a large multi-disciplinary team during a time critical situation (Booth & Allard, 2018) . As yet, the optimal MHP strategy remains unknown, and a recent survey of MHP therapy at six large research active level 1 European trauma centres confirmed wide variation in transfusion practice, highlighting the uncertainty that remains over best practice (Schafer et al, 2015) . A typical UK MHP is provided in Fig 2. Targeted or personalised haemorrhage therapy is an 
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Coagulation testing
Traumatic coagulopathy has been defined by a prolonged prothrombin time (PT) with a threshold international normalised ratio (INR) of 1Á2 (Frith et al, 2010) . More recently, viscoelastic assays definitions (rotational thromboelastometry -ROTEM or thromboelastography -TEG) have been advocated (Meyer et al, 2014; Hagemo et al, 2015; Moore et al, 2017) . Early recognition of a coagulopathy and subsequent monitoring is vital to both initiate and maximise resuscitation therapy. British Committee for Standards in Haematology guidelines recommend the use of serial standard laboratory tests (SLTs) taken every 30-60 min to monitor major haemorrhage (Hunt et al, 2015) . Supporting this idea, a small pilot randomised controlled trial (RCT) reported that SLT-guided transfusion led to less wastage of blood and blood components when compared to an empiric 1:1:1 fixed ratio transfusion practice (Nascimento et al, 2013) . Notably, viscoelastic haemostatic assays (VHA) were not evaluated in this study. There are however inherent difficulties with SLTs. Average turn-around-times are between 27 (Cotton et al, 2011b) and 77 min (Davenport et al, 2011) . In direct contrast, VHA can provide clinically useful results within 5 min of test start and provide information about several aspects of the coagulation process, including clot initiation, clot strength and fibrinolysis (Curry et al, 2018a) . It is important to recognise that VHA are fairly insensitive to mild/moderate fibrinolytic activity (Raza et al, 2013) and should not be used to withhold TXA therapy in a bleeding patient (Curry et al, 2018a) . Despite a large number of observational studies in trauma, high quality evidence supporting the use of ROTEM or TEG in trauma is lacking (Curry et al, 2018a) and currently the National Institute for Health and Care Excellence (NICE) does not recommend their use in guiding therapy for bleeding trauma patients (Whiting et al, 2015) .
Two RCTs evaluating the use of VHA in trauma have been published (Gonzalez et al, 2016; Innerhofer et al, 2017) . In a single centre study, Gonzalez et al (2016) reported a significant reduction in death at 28 days with VHA use: 20 deaths SLT (36Á4%) vs. 11 VHA (19Á6%), with shorter median times to death in the VHA arm (4Á2 vs. 10Á4 h). This study provides some evidence that VHA-guided transfusion (TEG-5000) may be beneficial in acute bleeding, over and above the empiric 1:1:1 transfusion. A second single centre RCT used ROTEM-guided thresholds to compare fresh frozen plasma (FFP) with single factor concentrates in trauma haemorrhage (Innerhofer et al, 2017) , with a primary endpoint of multiple organ failure. The study was terminated early due to high treatment failure in the FFP arm. The authors reported an association between clinically relevant bleeding and ROTEM measures, suggesting that ROTEM may be useful to guide trauma haemorrhage therapy. Finally, a multicentre European RCT (iTACTIC; NCT02593877) of nearly 400 patients utilising ROTEM or TEG has just completed recruitment and will report in early 2019. The trial compares SLT-guided transfusion therapy with VHA-guided therapy using a primary endpoint of 24-h survival free from massive transfusion. Derived from prospective coagulation profiles of over 2000 trauma patients (Bakaas-Aasen et al, 2018) , the VHA and SLT transfusion algorithms will provide further evidence as to the optimal method of guiding coagulation therapy during trauma haemorrhage (iTACTIC trial, NCT02593877).
Transfusion and adjunctive haemostatic therapies for trauma haemorrhage
Tranexamic acid
Fibrinolysis is common after injury, affecting up to 80% of trauma patients admitted to hospital (Raza et al, 2013) . The landmark trauma trial, CRASH-2 (CRASH-2 trial collaborators, 2010), demonstrated the importance of early modulation of the fibrinolytic pathway in trauma. This study of just over 20,000 patients showed that the administration of TXA (1 g bolus, followed by 1 g infusion over 8 h) reduced overall mortality [14Á5% deaths in TXA group vs. 16% in placebo group; relative risk (RR) 0Á91, 95% confidence interval (CI) 0Á85-0Á95; P = 0Á0035] and reduced risk of death from bleeding (4Á9% TXA vs. 5Á7% placebo; RR 0Á85, 95% CI 0Á76-0Á96; P = 0Á0077) (CRASH-2 trial collaborators, 2010). Importantly, subsequent analysis of the data, combined with data from a postpartum haemorrhage trialthe WOMAN study (WOMAN Trial Collaborators, 2017 ) -showed that the earlier TXA is administered, the greater the outcome benefit. Immediate therapy with TXA was associated with improved survival (Odds ratio 1Á72, 95% CI 1Á42-2Á10; P < 0Á0001) and the survival benefit then was shown to decrease by 10% for every 15-min delay in treatment, up to 3 h-(Gayet-Ageron et al, 2018). Interestingly, mortality benefit is lost when TXA is administered after 3 h of injury, with data from the CRASH-2 trial demonstrating harm for patients treated late, although the pathophysiological mechanisms for increased mortality have yet to be defined. Precisely how TXA improves survival also requires further mechanistic evaluation to clarify the relative effects of reduced bleeding, due to a direct anti-fibrinolytic action, and early modulation of the immune response (TXA activates the innate immune response) possibly altering clinical rates of infection, organ failure or systemic inflammatory response syndrome rates (Lord et al, 2014) . These questions aside, it is clear that TXA should be given to all trauma patients at risk of bleeding within the first 3 h of injury and, ideally, as quickly as possible (CRASH-2 trial collaborators, 2011).
Transfusion Management of Major Haemorrhagein Adults with Trauma WHEN LABORATORY RESULTS ARE AVAILABLE:
IF:
GIVE:
Platelet count <50 × 10 9 /l Platelets (1 adult dose; order when platelet count <100 × 10 9 /l) APTT and/or PT ratio >1.5 FFP (15-20 ml/kg) Fibrinogen <1.5 g/l Cryoprecipitate (2 pools)
Monitor for hyperkalaemia/ hypocalcaemia -aim for ionized Ca 2 > 1.0 mmol/l
Tranexamic acid
Trauma patients (<3 h from injury): give 1g bolus IV (ideally within 1 h of injury; do not administer after 3 h). This can be followed by a second bolus of 1g IV. Bleeding associated with haemodynamic compromise (e.g. heart rate >110 bpm, systolic BP <90 mmHg)
Take bloods
Transfusion management of major haemorrhage in adults with trauma. ABG, arterial blood gas; APTT, activated partial thromboplastin time; BP, blood pressure; Ca, calcium level; CS, clotting screen; FBC, full blood count; FFP, fresh frozen plasma; G+S, group and screen; Hb, haemoglobin concentration; IV, intravenously; MHP, major haemorrhage protocol; PT, prothrombin time; TEG, thromboelastography; U+E, urea and electrolytes; VBG, venous blood gas. 
Red blood cells
RBCs provide oxygen carrying capacity, contribute to restoration of adequate circulating volume and may play a role in haemostasis. There are no high-quality data providing evidence for target haemoglobin or haematocrit values during active haemorrhage, but the most recent European trauma guidelines recommend aiming for a haemoglobin of 70-90 g/l (Rossaint et al, 2016) . Over the last 5 years there has been increasing use of RBCs in the pre-hospital environment. No RCTs have been published in this setting, although a recent observational study from the London Air Ambulance reported on their use of pre-hospital RBCs (Rehn et al, 2018) . This retrospective historical cohort study reported a significant reduction in pre-hospital mortality in the group receiving RBCs (42Á2% vs. 27Á6%), although ultimately no overall survival benefit. A second UK study, comparing pre-hospital RBCs with a historical group receiving pre-hospital crystalloids, reported a reduction in mortality at both 6 h (10% vs. 18%) and 28 days (26% vs. 40%) (Griggs et al, 2018) . Results from both of these studies must be viewed within the constraints of historical cohorts -where, in these cases, the patients receiving RBCs may have also benefitted from other developments in trauma haemorrhage management.
Fresh frozen plasma
Plasma transfusion is central to the management of trauma haemorrhage. Since 2003, when ATC was found to be associated with increased transfusion need and higher mortality (Brohi et al, 2003) there has been extensive interest in the effects of early and/or high dose plasma therapy on clinical outcomes. Many observational studies, both prospective and retrospective, have been published since 2007 evaluating the effects of empiric, high ratio FFP:RBC transfusion strategies. The majority of studies concluded that higher ratios of FFP: RBC were associated with reduced mortality (Zehtabchi & Nishijima, 2009; Murad et al, 2010) , although many were confounded by survivor bias due to the retrospective nature of the data. Notably, no single FFP:RBC ratio (i.e. 1:1 vs. 1:1Á5) was found to be optimal, with few studies providing any mechanistic evidence for effect. FFP provides a source of coagulation factors necessary for thrombin generation although endogenous thrombin potential is maintained in the early phase after injury (Cardenas et al, 2014; Davenport et al, 2017) . The endothelial damage from trauma and restorative effects of plasma on the shed glycocalyx compared to crystalloid is one possible effect (Kozar et al, 2011; Watson et al, 2016) .
In an attempt to definitively answer the FFP:RBC ratio question, a large multicentre RCT evaluating the use of two transfusion regimens in adult trauma haemorrhage patientsthe PROPPR trial (Holcomb et al, 2015) -was conducted at 12 Level 1 trauma centres in North America. An FFP:-platelets:RBC ratio of 1:1:1 was compared to 1:1:2 in 680 participants with a combined primary endpoint of 24-h and 30-day mortality (see Table I ). The study was powered to detect a 10% difference in 24-h mortality (11% vs. 21%) and a 12% difference in 30-day mortality (23% vs. 35%), with 95% and 92% power, respectively. Mortality was not shown to be significantly different between arms, either at 24 h (12Á7% in 1:1:1 group vs. 17Á0% in 1:1:2 group; P = 0Á12) or at 30 days (22Á4% vs. 26Á1%, respectively; P = 0Á26), although the Kaplan Meier survival curves show a clear separation from 3 h of injury. However, the intervention was reported to significantly reduce the secondary endpoint of death due to bleeding, the most common cause of death up to 24 h (1:1:1 group 9Á2% vs. 14Á6% in 1:1:2 group; P = 0Á03). In addition, more patients in the 1:1:1 group achieved haemostasis (as defined by a study-specific haemorrhage assessment tool) than in the 1:1:2 group (86% vs. 78%, respectively; P = 0Á006). The 1:1:1 group received more plasma (median of 7 units vs. 5 units, P < 0.001) and platelets (12 units vs. 6 units, P < 0Á001) and similar amounts of red blood cells (9 units) over the first 24 h. No significant differences were reported for adverse events, in particular organ failure, transfusion-related adverse events, sepsis and thromboembolism (Holcomb et al, 2015) .
These data have been used by many to inform local transfusion practice for trauma, because they are the highest quality data available around early FFP use, although the results are inconclusive -with many UK centres following NICE guidance, which recommends FFP:RBC in the ratio of 1:1 (National Clinical Guideline Centre 2016). However, the use of immediate platelet transfusion in a 1:1:1 ratio is not universally accepted, with many physicians unclear about how to adopt the results of PROPPR, where two interventions were evaluated simultaneously, e.g. high ratio FFP and early platelet administration (see below).
Following the PROPPR study, research has focussed on even earlier delivery of plasma with two prehospital RCTs published this year (Table I ). The COMBAT study was a single centre RCT that compared 2 units of frozen plasma (thawed in the land ambulance) with normal saline in 144 trauma patients with haemorrhagic shock (Moore et al, 2018) . There was no difference in 28-day mortality, safety profiles or transfusion use; however; prehospital times were short (median times from injury to admission were under half an hour) and just over half of patients required further transfusion in hospital. In contrast, the PAMPer Study, a larger, multi-centre, cluster-randomised study, compared 2 units AB, or A with low anti-B titre, thawed plasma with standard of care -where crystalloids were the resuscitation fluid of choice . In the 501 patients randomised, mortality was significantly lower in the plasma group vs. control (23Á3% vs. 33Á0%, P = 0Á03). The separation in mortality rates was first These data are likely to direct mainstream clinical practice and, certainly, some UK helicopter emergency medical services (HEMS) already carry plasma on board. Nevertheless, thawed FFP has a relatively short shelf life once thawed (3-5 days) (3 days in the UK and up to 5 days in Canada and the US) and this confers practical challenges to blood banks and HEMS services. Additionally, it is known that levels of labile coagulation factors, such as FVIII and FV, fall during storage of thawed plasma. Lyophilised and dried plasmas have been evaluated in an attempt to avoid these difficulties.
Lyophilised plasma
The obvious advantage of using lyophilised plasma is the lack of need for refrigeration (a challenge particularly for military settings). Lyophilised plasma is most commonly manufactured by first freezing the plasma, then dehydrating it by sublimation under vacuum for several days. Less commonly, plasma can be spray dried by atomising the liquid plasma and exposing it briefly to a stream of hot, dry gas (Pusateri et al, 2016) . Currently there are three available lyophilised plasmas (Table II) : (i) French Lyophilised Plasma (F-LyP), produced by the French Military Blood Institute; (ii) LyoPlas N-w, a single donor product produced by the German Red Cross; (iii) Bioplasma FDP, produced by National Bioproducts Institute, South Africa. Lyophilised plasma has been used both in military (Shlaifer et al, 2017) and austere civilian (Sunde et al, 2015) settings. A small (n = 48) single centre open label RCT (NCT02750150, TRAUCC -Transfusion for Trauma-induced Coagulopathy and Fibrinogen Concentration trial) compared F-LyP with FFP on arrival at hospital for treatment of trauma haemorrhage and TIC (Garrigue et al, 2017) (Table I ). The authors reported that F-LyP achieved a significantly higher fibrinogen level at 45 min [baseline-adjusted mean difference, 0Á29 g/l; 95% confidence interval (CI), 0Á08-0Á49, P = 0Á006] and at 6 h (baselineadjusted mean difference, 0Á51 g/l; 95% CI, 0Á14-0Á88, P = 0Á008) and a greater improvement in coagulation factors FII and FV and PTr, both at 45 min and 6 h. F-LyP also reduced fibrinogen concentrate use and 30-day mortality was 22% (F-LyP) and 29% (FFP). A UK multicentre pre-hospital trauma study is currently ongoing (RePHILL, Resuscitation with Pre-Hospital Blood Products, EME 14/152/14) and is comparing 2 units RBCs and 2 units LyoPlas N-w vs. crystalloid resuscitation in 490 patients using a primary endpoint of lactate clearance and mortality in hospital. 
Platelets
Platelet dysfunction is common after trauma and it would make sense intuitively to transfuse platelets to improve haemostatic potential in bleeding patients. However, to date, the effects of platelet transfusion remain unclear. For example, there are few observational studies that show benefit solely from platelet transfusion (Perkins et al, 2009; Inaba et al, 2010; Shaz et al, 2010) and, notably, all three of these studies suffered from significant survivorship bias (Hallet et al, 2013) , whereas the two observational studies evaluating platelet effect that were deemed of higher quality, i.e. without survivor bias (Cotton et al, 2008; del Junco et al, 2013) were unable to show an overall mortality benefit. Looking more mechanistically, Vuillamy et al (2017) reported on the haemostatic effects of transfused platelets in 161 UK trauma patients who were actively bleeding, and showed that platelet transfusion was associated with increased PAI-1, reduced tPA and a decrease in ROTEM lysis measurements, but no improvement in platelet aggregation parameters. These results suggest platelet transfusion given during active bleeding may mitigate the fibrinolysis commonly seen. At present in the UK, many centres are using platelets in their second haemorrhage 'pack' and advising their use early within this pack (authors own unpublished observations).
Aside from the, as yet, unclear role that platelets have during traumatic bleeding, there are also practical issues. In many smaller hospitals, as well as in austere military settings, the ability to provide standard platelet concentrates (PCs) is challenging, mostly due to their short shelf life (between 5-7 days) and their specific storage requirements i.e. room temperature and continuous agitation.
Cryopreservation and cold storage techniques have been proposed as potential methods to prolong PC shelf life by reducing platelet metabolism and bacterial proliferation. Cryopreservation involves suspending platelets in dimethyl sulfoxide followed by frozen storage at À80°C, with subsequent thawing and resuspension in either plasma or saline (Marks, 2018) . The wars in Iraq and Afghanistan highlighted the need for a safe PC with a long shelf life, and cryopreserved platelets (CRYO-PLT) have been issued since 2011 by the Netherlands Military Blood Bank (Lelkens et al, 2006) , with promising clinical results (a reduction in mortality rates with higher platelet ratios) (Noorman et al, 2016) .
However, CRYO-PLT appear more activated than standard PCs, with higher CD62P expression and increased phosphatidylserine exposure (Johnson et al, 2014) , leading to concerns about the hypercoagulability of this product. In vitro studies have demonstrated that CRYO-PLTs contain 15 times as many microparticles as platelets stored at room temperature (RT-PLTs) and the microparticles confer the most haemostatic effect (Raynel et al, 2015) . However, clinical studies so far have reported positive outcomes with good haemostatic efficacy and no increased thrombotic risk (Noorman et al, 2016) . Nevertheless, even if CRYO-PLTs are established as safe and effective in civilian settings, there are significantly greater preparation times and equipment costs associated with PC cryopreservation, and thawing may be a barrier to widespread use. To date, CRYO-PLTs are approved for general use in France and for military operations in the Netherlands and Germany (Dumont et al, 2014) , with other countries developing their use (Marks, 2018) .
Cold-stored PCs (2-6°C) are an alternative to CRYO-PLTs and are easier to prepare and store. Cold-stored PCs have decreased bacterial contamination risks and improved haemostasis compared with RT-PLTs (Nair et al, 2014; Pidcoke et al, 2014) . However, cold platelets are cleared from the circulation more rapidly than RT-PLTs, with an average life span of 1Á3 days (vs. 3Á9 days for RT-PLTs) (Reddoch et al, 2014) . However, it could be argued that, for rapidly bleeding trauma patients, the most important objective is to arrest life-threatening bleeding rather than preserve platelet longevity in vivo. Indeed, in 2015, the US Food and Drug Administration (FDA) approved cold-stored PCs for resuscitation of bleeding patients in the US and data on their clinical efficacy in this setting are awaited. This development may lead to blood banks routinely storing platelets both at room temperature and at 2-6°C, depending on the indication for transfusion.
Lyophilised platelets are the fourth and final type of PC that are currently being evaluated. There are some promising pre-clinical studies using lyophilised platelets with good haemostasis achieved in a porcine model using species-specific lyophilised platelets (Inaba et al, 2014) but there have been no clinical studies demonstrating efficacy in trauma yet (Cap & Perkins, 2011) .
Fibrinogen replacement
Fibrinogen is critical for effective haemostasis. It is the precursor of fibrin and is an important mediator of platelet aggregation, via the platelet receptor glycoprotein IIb/IIIa. Once cleaved by thrombin, fibrinogen forms a network of insoluble polymerised fibrin strands that act as a 'mesh' to support the formation of a stable clot. Both cryoprecipitate and fibrinogen concentrate are given during major haemorrhage to ameliorate hypofibrinogenaemia, and the choice of the blood component used depends commonly on the country of the treating physician (see Table III ) (Wong & Curry, 2018) .
Observational data support the importance of fibrinogen supplementation and have shown that low fibrinogen levels are an independent predictor of mortality (Rourke et al, 2012) , as well as bleeding (Sch€ ochl et al, 2011a) . Despite it being known for over 20 years that fibrinogen is one of the first clotting factors to fall to clinically low levels (Hiippala et al, 1995) , the central importance of fibrinogen replacement for effective haemostasis in major bleeding has only recently been recognised. This shift in thinking is likely to be a major reason behind the reports of increased cryoprecipitate use Higher quality data from RCT data are scarce -with only three pilot/feasibility studies having been published so far (Curry et al, , 2018b Nascimento et al, 2016) , and one RCT comparing speed of delivery of fibrinogen concentrate to cryoprecipitate reporting preliminary data at a trauma conference this month (FEISTY, NCT02745041). The three pilot studies evaluated the feasibility of administering (i) CRYOSTAT-1 (ISRCTN55509212): 4 g fibrinogen (as 2 pools of cryoprecipitate); (ii) FiiRST (NCT02203968): 6 g fibrinogen concentrate and (iii) EFIT-1 (ISRCTN67540073): 6 g fibrinogen concentrate at timescales of 90, 60 and 45 min. Together the data show that the average time to fibrinogen delivery is between 45-60 min from admission and those patients in the intervention arms maintained their fibrinogen levels much higher during active bleeding than in the comparator arms (Table IV) . The studies do not show an increase in thromboembolic risk with fibrinogen replacement, and overall no significant effect on mortality. These data provide preliminary data showing that early fibrinogen is safe and it is feasible to give it in a challenging clinical environment, however, none of the studies provide clinical efficacy outcome data.
CRYOSTAT-2 (ISRCTN 14998314) is a multicentre, international (UK-wide and selected US sites) trauma trial evaluating whether 6 g of early fibrinogen replacement (3 pools of cryoprecipitate) reduces mortality at 28 days in adults with major trauma haemorrhage (Marsden et al, 2018) . Target recruitment is 1568 patients and is due to be completed in 2020. This trial will report for the first time whether fibrinogen replacement affects mortality and will undoubtedly bring about changes in transfusion practice and how fibrinogen is prioritised during active haemorrhage. Until then, it is likely that fibrinogen replacement will continue to be given empirically (or to maintain a fibrinogen level more than 1Á5 g/l) as part of the MHP for trauma haemorrhage, based on consensus and observational data.
What about the differences between cryoprecipitate and fibrinogen concentrate (Table III) ? The FEISTY study has directly compared speed of delivery of the two products in trauma and full results are awaited. Given the costs and logistics of a head-to-head trial, for the time-being it appears that industry is unlikely to fund a direct comparison between • SD plasma UK:
• SD plasma • MB treated (given in UK to patients born after 1/1/1996) these two products in a clinical trial powered for patient outcomes. Nevertheless, many view fibrinogen concentrate as a superior product to cryoprecipitate with reasons including: standardisation of production -vials contain a known fibrinogen concentration; lyophilisation making it easily portable and not requiring storage or thawing in blood bank; viral inactivation; and a consideration for the UK is a probable lower risk for variant Creutzfeldt-Jakob disease transmission (Wong & Curry, 2018) . Gram for gram, fibrinogen concentrate is four times the cost of cryoprecipitate. On average it takes at least 10 min to reconstitute fibrinogen concentrate (Innerhofer et al, 2017) and once reconstituted, it must be administered within 24 h. By way of contrast, cryoprecipitate takes 17-20 min to defrost and once defrosted, it has a shelflife of 4 h, increasing its potential for wastage. Blood services have been addressing this particular issue by exploring the effects of extended post-thaw shelf-life, both to 24 h (Sheffield et al, 2016) and 72 h (Green et al, 2016) . In both studies, no significant reductions in fibrinogen, FVIII, FXIII or von Willebrand factor were found after storage at 20-24°C at either time point and ROTEM parameters were similar at 72 h -suggesting maintenance of haemostatic potential (Green et al, 2016) . However, there remains concern about bacterial contamination in thawed cryoprecipitate, which would be stored at room temperature, and this potential risk currently prohibits the extension of the shelf-life. There are theoretical reasons why cryoprecipitate may confer advantages over fibrinogen concentrate in trauma haemorrhage -for example increased levels of FXIII and alpha-2-anti-plasmin may confer increased clot resistance to fibrinolysis. These theories have not yet been explored, and in the UK, at present, cryoprecipitate remains the only licensed product for fibrinogen replacement in acquired bleeding.
Whole blood
There have been on-going questions about the role of whole blood in the management of trauma haemorrhage for many years. Many clinicians advocate its use because it provides a balanced product and returns to the patient 'what has been lost'. There are several forms of whole blood: fresh whole blood (FWB), cold stored whole blood (CWB) and cold fresh whole blood (CFWB), a product used within 48 h of collection (Table V) . Whole blood that has been stored and tested for transfusion-transmitted infections (TTI) has been approved for use in the US by the FDA for massive blood loss. FWB is not licensed, however, due to its potential risks, which include TTI (a report of 10 000 FWB transfusions confirmed 1 hepatitis C virus and 1 human T-lymphotropic virus seroconversion and one death from transfusion-associated graft-versus-host disease) and the increased risk of ABO-mismatched blood being provided (Cap et al, 2018) .
RCT evidence for the use of WB in trauma comes from a single centre study of 107 patients who were randomised 39 (14) 46 (25) 50 (8) 51 (9) 67 ( to receive modified WB (where platelets were removed during leucofiltration) or standard blood component therapy (Table I) . The primary endpoint, 24-h transfusion volume, was not different between arms, although in a subgroup analysis there was significant reduction in transfusion need in patients without traumatic brain injury. FWB has been used in military operations, especially in austere or far forward environments (Daniel et al, 2016) , and evidence from the battlefield has shown favourable outcomes when compared to component therapy (Nessen et al, 2013) . The military use an emergency donor panel for collection and delivery of FWB , and this provides rapid access to warm FWB in the vicinity of the patient, without need for storage, transport or refrigeration. The blood is collected from pre-screened donors but does not undergo full TTI-testing prior to transfusion. This approach only allows for a small number of donations from each volunteer, invalidates the donor from giving further donations for 6-8 weeks, and needs high-quality systems to facilitate its conduct. Ideally, provision of FWB requires screening to avoid transmission of blood-borne infections (Spinella et al, 2007) . Furthermore, FWB transfused without leucoreduction, in an attempt to maintain platelet function, may lead to an increase in the risk of acute lung injury and graft-versus-host disease (Gilstad et al, 2012) .
Pre-screened, leucoreduced CWB may be a safer product, but these modifications impair platelet function and clotting capacity (Siletz et al, 2017) . However, there is some evidence that CWB can be collected and stored for up to 14 days without detriment to its haemostatic function . After 2 weeks storage it seems that the haemostatic function becomes much more variable and, in particular, platelet function seems to be lost (Cap et al, 2018 ).
An additional practical issue that limits easy use of WB is the need to transfuse ABO-compatible blood. More recently, work has been undertaken to look at the safety of low-titre, group O positive, leucoreduced, CWB (LTOWB) as a universal WB product. This is particularly attractive for use in the pre-hospital or military setting. An observational civilian study of 172 bleeding trauma patients (102 nongroup O and 70 group O) who received between 1-4 units of LTOWB was recently reported (Seheult et al, 2018) . No increased haemolysis markers (lactate dehydrogenase, haptoglobin, bilirubin) were noted in the non-group O when compared with the group O patients and no adverse transfusion reactions were reported (Seheult et al, 2018) . This study has led to the use of LTOWB units in 6 US study sites as standard clinical practice. In the UK, the National Health Service Blood and Transplant has recently embarked on the clinical evaluation of a "Red Cell and Plasma" product (leucodepleted and platelet filtered) for use with the London Air Ambulance and work continues on developing a platelet rich, leucodepleted product quality assured for UK practice. 
Non-fibrinogen factor concentrates
Single (e.g. recombinant activated FVII, rFVIIa, FXIII) and combined factor concentrate therapies (e.g. prothrombin complex concentrates, PCC) have been used for traumatic bleeding. Two RCTs have been published looking at the effectiveness of rFVIIa in trauma (Boffard et al, 2005; Hauser et al, 2010) . The primary endpoint in the first trial was transfusion requirement; the second trial, powered for mortality, was closed early due to slow recruitment and futility. Both reported a reduction in RBC use following rFVIIa administration in blunt trauma but no improvement in mortality. A systematic review of the rFVIIa RCT literature, including trauma, indicated no evidence to support rFVIIa as standard treatment for traumatic bleeding and raised concerns about increased risks of thrombotic events (Simpson et al, 2012) . The RETIC trial (Innerhofer et al, 2017) compared FFP with factor concentrates (including fibrinogen and FXIII) using ROTEM-guided triggers. It was not possible to differentiate the effect of FXIII in this study and no other RCT has evaluated FXIII in the trauma setting. PCC are plasma-derived coagulation factor concentrates that contain 3 or 4 vitamin K-dependent factors at high concentration and are commonly used to reverse vitamin-K antagonist therapy. PCC has been used also as first line therapy for TIC in some countries. Two observational European cohort studies described the use of PCC in trauma, as an adjunct to fibrinogen concentrate, and reported reduced transfusion need in one but no mortality improvement in either study (Nienaber et al, 2011; Sch€ ochl et al, 2011b) . A US group compared 4-factor PCC (4-PCC) plus FPP (n = 40) with FFP alone (n = 80) in an observational study and reported reduction in RBC (7 vs. 9units) and FFP (5 vs. 7 units) use, as well as a lower mortality (25% vs. 33%) in the PCC plus FFP arm. No difference was seen in thromboembolic events (2Á5% vs. 1Á2%) (Jehan et al, 2018) . No RCT data are available, and there remain unanswered questions about the safety of PCC in this setting, particularly in relation to thrombotic events (Grottke et al, 2011) .
Future directions
The transfusion strategies that have been employed to date have focussed on 'replacing what is lost/missing' and this could be thought of as a simplistic view. Certainly, it is an important part of the resuscitation process, and significant improvements in mortality have been linked to this approach. There is much more work that is currently ongoing, looking at how to maximise the potential of the blood and blood components that are available both in pre-clinical or clinical settings, including better storage methods. The increase in numbers of small and large RCTs is also encouraging, as these studies provide clinicians with high quality evidence about how to improve clinical practice and patient outcomes. One important strategy that will continue to support high quality trauma research is a focus on strengthening collaborative approaches, using international networks such as the International Trauma Research Network (INTRN) or the Biomedical Excellence for Safer Transfusion (BEST) collaborative. These types of international networks will facilitate and guide large, well-co-ordinated, high quality studies in how best to treat major trauma haemorrhage with transfusion and haemostatic therapies.
However, using a 'replace what is missing' strategy alone fails to address the endothelial activation (the 'endotheliopathy' of trauma) that goes hand-in-hand with the physiological changes of shock and severe haemorrhage (Naumann et al, 2018 ). An additional focus for both civilian and military settings will be to address these endothelial changes, and the inflammatory processes, as well as direct transfusion therapy towards a more personalised approach. The added focus for military settings will also be on the delivery of haemostatic products that do not require refrigeration, are temperature stable, lightweight, safe and can be carried easily.
Conclusions
The world of trauma transfusion has seen an explosion of high quality small and large RCTs which have led to marked practice changes and improved mortality globally. The next few years will probably see further significant shifts in the management of haemostatic resuscitation.
